The Compensation Committee of the Board of Directors of Ligand Pharmaceuticals Incorporated approved a promotion for Mr. Matthew Korenberg to Executive Vice President, Finance and Chief Financial Officer and for Mr. charles s. berkman to Senior Vice President, General Counsel and Secretary.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
96.67 USD | -2.76% |
|
+11.27% | +35.35% |
Jul. 08 | Ligand to Acquire Apeiron for $100 Million in Cash, Plus Up to $28 Million Based on Royalties | MT |
Jul. 08 | Ligand Pharmaceuticals Incorporated Revises Earnings Guidance for the Year 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.35% | 1.74B | |
+63.05% | 856B | |
+39.42% | 631B | |
-4.78% | 359B | |
+17.52% | 325B | |
+8.43% | 297B | |
+14.19% | 244B | |
+5.81% | 234B | |
+16.77% | 226B | |
+14.63% | 177B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Announces Executive Changes